Interested in reading how B.R.I.D.G.E. could benefit your search for the right database or registry? Download our latest trifold brochure, then share it with colleagues and friends. Contact us for more information.
For more information or additional guidance on SEER-CAHPS, please contact the SEER-CAHPS staff at NCISEERCAHPS@mail.nih.gov.
You may also contact the SEER-CAHPS staff by completing this contact form at https://healthcaredelivery.cancer.gov/seer-cahps/contact.html
1. Dibble KE, Jin M, Deng Z, Connor AE. Associations between CAHPS scores of patient care experiences and breast cancer survival among senior female survivors:a SEER-CAHPS analysis. Women Health. 2025 Apr;65(4):376-387.
2. Pandit AA, Halpern MT, Gressler LE, Kamel M, Payakachat N, Li C. Association of race/ethnicity and patient care experiences with healthcare utilization and healthcare costs among prostate cancer survivors: A SEER-CAHPS study. J Geriatr Oncol. 2024 Apr;15(3):101748.
3. Pandit AA, Halpern MT, Gressler LE, Kamel M, Payakachat N, Li C. Association of race/ethnicity and patient care experiences with receipt of definitive treatment among prostate cancer survivors: a SEER-CAHPS study. Cancer Causes Control. 2024 Apr;35(4):647-659.
4. Yoon PS, Navarro S, Barzi A, Ochoa-Dominguez CY, Arizpe A, Farias AJ. Racial and ethnic disparities in self-reported general and mental health status among colorectal cancer survivors: impact of sociodemographic factors and implications for mortality-a SEER-CAHPS study. Qual Life Res. 2024 Mar;33(3):793-804.
5. Arevalo M, Pickering TA, Vernon SW, Fujimoto K, Peskin MF, Farias AJ. Racial/ethnic disparities in the association between patient care experiences and receipt of initial surgical breast cancer care: findings from SEER-CAHPS. Breast Cancer Res Treat. 2024 Feb;203(3):553-564.
6. Malik MS, Subrize MW, Ou J, Curry MP, Parikh ND, Novack V, Weinstein JL, Ahmed M, Sarwar A. Association between Patient Experience Scores and Low Utilization of Hepatocellular Carcinoma Treatment in the United States: A Surveillance, Epidemiology, and End Results-Consumer Assessment of Healthcare Providers and Systems Analysis (SEER-CAHPS). J Vasc Interv Radiol. 2024 Jan;35(1):102-112.e5.
7. Pandit AA, Patil NN, Mostafa M, Kamel M, Halpern MT, Li C. Rural-Urban Disparities in Patient Care Experiences among Prostate Cancer Survivors: A SEER-CAHPS Study. Cancers (Basel). 2023 Mar 23;15(7):1939.
8. Arevalo M, Pickering TA, Vernon SW, Fujimoto K, Peskin MF, Farias AJ. Do breast cancer survivors with a recent history of clinical depression report worse experiences with care? A retrospective cohort study using SEER-CAHPS data. Cancer Med. 2023 Jan;12(2):1949-1960.
9. Pandit AA, Gressler LE, Halpern MT, Kamel M, Payakachat N, Li C. Racial/Ethnic Disparities in Patient Care Experiences among Prostate Cancer Survivors: A SEER-CAHPS Study. Curr Oncol. 2022 Nov 1;29(11):8357-8373.
10. Wardrop RC, Cass AL, Quinn SA, Wercholuk AN, Parikh AA, Snyder RA. Racial and ethnic differences in patient ratings of colorectal and non-small-cell lung cancer care: A SEER-CAHPS study. Cancer Causes Control. 2022 Sep;33(9):1125-1133.
In addition to our online compendium of healthcare database profiles, the B.R.I.D.G.E. TO DATA® team also provides assistance for your database-related projects. Whether it's conducting comprehensive database searches, identifying data sources, communicating with data vendors, or developing a customized searchable database repository, our team is ready to help.
B.R.I.D.G.E. TO DATA is a unique one-stop for all databases you might need for any research purpose. A unique user-friendly directory to search for databases from all over the world, you can easily grasp what each database can offer you without wasting time on each one.
We are excited to introduce the Norwegian Surveillance System for Communicable Diseases as our 400th profile. Established in 1975, the system relies on the reporting of infectious diseases from healthcare providers and laboratories across the country. The data collected are used to develop public health policies, monitor disease trends, and respond to outbreaks.
2022 had us busy profiling databases from around the world (currently 400), including the first ones from six countries. We made several enhancements and also lowered the “global” subscription rate to make our resource more affordable to locate databases of interest. Would you complete our 2-minute survey regarding how you could benefit from B.R.I.D.G.E.?
Christine Bergland
Executive Director, Division of Health Data and Digitalisation
Norwegian Institute of Public Health
NORWAY
Email: Christine.Bergland@fhi.no
For data access, applications must be submitted through https://helsedata.no/.
General contact information for MSIS -
Phone: (+47) 2107 7000
1. Nordstrand K, Berild JD. Increase in tuberculosis notification rates among newly arriving male Ukrainian refugees to Norway, 2022 to 2024. Euro Surveill. 2025;30(34):2500633.
2. Tipu JH, Sivertsen A, Afset JE, Sandven L, Brekke H, Lund HM, et al. Cryptosporidium species and subtypes in Norway: predominance of C. parvum and emergence of C. mortiferum. Emerg Microbes Infect. 2024;13(1):2412624.
3. Salamanca BV, Cyr PR, Bentdal YE, Watle SV, Wester AL, Strand ÅM, et al. Increase in invasive group A streptococcal infections in children and older adults, Norway, 2022 to 2024. Euro Surveill. 2024;29(20):2400242.
4. Colby E, Molden T, Olsen J, Kelly P, Pilz A, Halsby K, et al. Estimated incidence of symptomatic Lyme borreliosis cases in five southern coastal counties in Norway, 2022. APMIS. 2024;132(11):832-842.
5. Danielsen AS, Elstrøm P, Eriksen-Volle HM, Hofvind S, Eyre DW, Kacelnik O, et al. The epidemiology of multidrug-resistant organisms in persons diagnosed with cancer in Norway, 2008-2018: expanding surveillance using existing laboratory and register data. Eur J Clin Microbiol Infect Dis. 2024;43(1):121-132.
6. Engebretsen S, Aldrin M. Effect of testing criteria for infectious disease surveillance: the case of COVID-19 in Norway. PLoS One. 2024;19(8):e0308978.
7. Leonhardt M, Bramness JG, Lien L. Incidence of SARS-CoV-2 and all-cause mortality in persons with co-occurring substance use disorder and mental illness during the pandemic: a Norwegian cohort study. Soc Psychiatry Psychiatr Epidemiol. 2024;59(8):1379-1387.
8. Meijerink H, Shelil M, Jani-Bolstad J, Dvergsdal ET, Madslien EH, Wilberg M, et al. Does integration with national registers improve the data completeness of local COVID-19 contact tracing tools? A register-based study in Norway, May 2020-September 2021. BMC Health Serv Res. 2024;24(1):96.
9. Seppälä E, Dahl J, Veneti L, Rydland KM, Klüwer B, Rohringer A, et al. COVID-19 and influenza vaccine effectiveness against associated hospital admission and death among individuals over 65 years in Norway: a population-based cohort study, 3 October 2022 to 20 June 2023. Vaccine. 2024;42(3):620-628.
10. Øien H, Gjesvik J, Skyrud KD, Rotevatn TA, Grøsland M. All-cause mortality and hospital admissions for nursing home residents during the COVID-19 pandemic: a Norwegian register-based cohort study. BMC Med. 2024;22:1-14.
Starting in 1997, the Icelandic Register of Communicable Diseases includes diseases, agents causing diseases and events, immunisations, and use of antimicrobial drugs, and is intended to be of use in preventive measures and in epidemiological research. Notifiable communicable diseases which can pose a threat to public welfare are subject to registration.
Sigríður Haralds Elínardóttir
Head of Division, Health Information
Directorate of Health
Katrínartún 2
IS – 105 Reykjavík
ICELAND
Phone: +354 510 1900
Email: sigridur.haraldsd.elinardottir@landlaeknir.is
Directorate of Health
Katrínartún 2
105 Reykjavík
Kt. 710169-5009
ICELAND
Tel: + 354 510 1900
E-mail: mottaka@landlaeknir.is
N/A
